Plantar Fasciitis Treatment Market

The increasing incidence of obesity is driving the market growth

Market CAGR for Plantar Fasciitis Treatment is being driven by the increasing incidence of obesity. Foot pain resulting from repetitive strain injuries is frequently attributed to planter fasciitis. The sole becomes painful as a result of it affecting the heel area of the foot. This kind of inflammation is specific to muscles. People who spend a lot of time standing on hard surfaces are more likely to experience it. Activities involving foot stretches assist people in reducing their plantar fasciitis pain.

Planter fasciitis is a condition that pains the foot when walking because of inflammation and irritation of the strong band of tissue supporting the arch of the foot.

Additionally, An increase in the number of occurrences with plantar fasciitis and a rise in the use of orthotics are driving the   market. The potential for growth for stakeholders is increased by the fact that a variety of treatments are becoming a strong ally in the battle against severe heel pain brought on by plantar fasciitis. Additionally, since obese people are more likely to get plantar fasciitis, the growing obesity population is fueling the market's expansion.

In a study published in The Journal of Pain, the National Centre for Integrative and Complementary Health (NCCIH) found a substantial correlation between plantar fasciitis and body mass index (BMI).

Growing older is a risk factor for plantar fasciitis to occur, and as the world's population becomes older, the number of people who will likely develop foot-related problems rises, increasing the need for treatment options. Increased physical activity, obesity, and changing lifestyles are some of the causes linked to the rising occurrence of plantar fasciitis, which is driving up demand for treatment solutions. Plantar fasciitis treatment options are becoming less intrusive and more successful due to ongoing improvements in medical technologies, including novel treatment modes and therapies.

Plantar fasciitis and other foot-related injuries are becoming more common as a result of increased involvement in sports and physical activities. The need for efficient treatment alternatives among athletes and active people is driving market expansion.

For instance, The Centers for Prevention and Control of Diseases (CDC) released revised data in January 2022, showing that 40,698 individuals died in automobile accidents in 2020, compared to 200,995 deaths from unintentional injuries. The same data indicates that in 2020, there were 97.9 million trips to emergency rooms and 24.8 million visits to physicians in the US. Thus, result in driving the Plantar Fasciitis Treatment market revenue.

The Global Plantar Fasciitis Treatment Market Industry is benefiting from the increasing healthcare expenditure observed globally. Governments and private sectors are allocating more resources towards healthcare, which includes funding for orthopedic treatments. In 2024, the market is projected to reach 2.26 USD Billion, reflecting this trend. As healthcare systems evolve and prioritize pain management and rehabilitation, more funds are directed towards innovative treatment solutions for conditions like plantar fasciitis. This financial support is likely to enhance research and development, leading to the introduction of new therapies and products in the market, thereby stimulating growth.

Increased awareness and education regarding plantar fasciitis are pivotal in shaping the Global Plantar Fasciitis Treatment Market Industry. Health campaigns and educational programs aimed at both healthcare professionals and the general public are fostering a better understanding of the condition. This heightened awareness encourages individuals to seek timely treatment, which can lead to improved quality of life. Furthermore, educational initiatives often highlight the importance of early intervention, which can prevent chronic issues. As more people become informed about plantar fasciitis, the demand for effective treatment options is expected to rise, positively impacting the market.

Technological innovations in treatment modalities are significantly influencing the Global Plantar Fasciitis Treatment Market Industry. The introduction of advanced therapies, such as shockwave therapy and regenerative medicine, offers patients more effective options for pain relief and recovery. These innovations not only enhance treatment efficacy but also improve patient outcomes, leading to increased adoption. Moreover, the integration of telemedicine allows for remote consultations and follow-ups, making treatment more accessible. As these technologies continue to evolve, they are likely to attract more investment and research, thereby driving growth in the Global Plantar Fasciitis Treatment Market Industry.

The Global Plantar Fasciitis Treatment Market Industry is experiencing growth driven by the increasing prevalence of plantar fasciitis among various demographics. Factors such as obesity, aging populations, and sedentary lifestyles contribute to this rise. For instance, studies indicate that approximately 10% of the population may experience plantar fasciitis at some point in their lives. This growing incidence necessitates effective treatment options, thereby expanding the market. As awareness of the condition increases, more individuals seek medical intervention, further propelling the demand for treatment solutions in the Global Plantar Fasciitis Treatment Market Industry.

Demographic shifts, particularly the aging population and changing lifestyles, are crucial drivers of the Global Plantar Fasciitis Treatment Market Industry. As the global population ages, the incidence of musculoskeletal disorders, including plantar fasciitis, is expected to rise. Additionally, modern lifestyles characterized by prolonged standing and high-impact activities contribute to the prevalence of this condition. By 2035, the market is anticipated to grow to 23.0 USD Billion, indicating a strong correlation between demographic trends and market expansion. This growth underscores the need for effective treatment options tailored to diverse populations, further driving the market.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Plantar Fasciitis Treatment market area will dominate this market. The need for efficient therapies is exacerbated by plantar fasciitis's high incidence in North America. Plantar fasciitis is more common in older people, obese people, and people who engage in particular physical activities.

Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.

Figure2:  Plantar Fasciitis Treatment Market Share By Region 2023 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe Plantar Fasciitis Treatment market has the second-largest portion of the market, as a result of a rise in lifestyle-related factors' incidence and growing awareness of their diagnosis. Further, the German Plantar Fasciitis Treatment market had the biggest market share, and the UK Plantar Fasciitis Treatment market was the fastest growing market in the European region

The Asia-Pacific Plantar Fasciitis Treatment Market is anticipated to expand between 2025 and 2034 at the quickest CAGR. This is because of the rise in sports and physical activity as well as easier access to healthcare. Moreover, China’s Plantar Fasciitis Treatment market had the biggest market share, and the Indian Plantar Fasciitis Treatment market was the fastest growing market in the Asia-Pacific region.

Leading market players are putting a lot of money on R&D to expand their product lines, which will help the market for weight reduction products grow. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. to grow and endure in an increasingly cutthroat and dynamic market, Plantar Fasciitis Treatment industry must provide reasonably priced goods.

Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  Plantar Fasciitis Treatment industry to help customers and expand the market segment. In recent years, the Plantar Fasciitis Treatment industry has provided some of the biggest benefits to medicine. Major players in the Plantar Fasciitis Treatment market, including Bayer AG (Germany), SUPERFEET WORLDWIDE, LLC (U.S.), Bauerfeind USA Inc. (Germany), Ottobock (Germany), Recover Sports Medicine (Australia), Shapecrunch (India), and others, are attempting to increase market demand by investing in research and development operations.

One of the biggest pharmaceutical and biomedical corporations in the world is Bayer AG, a multinational pharmaceutical and biotechnology firm based in Germany. Bayer, which has its headquarters in Leverkusen, is a company that deals in pharmaceuticals, consumer healthcare goods, seeds, agricultural chemicals, and biotechnology products. The business is included in the EURO STOXX 50 index of stock market companies. In June 2021, The business declared that it has acquired PSMA Therapeutics Inc. and Noria Therapeutics Inc., acquiring the rights to several actinium-225-based cancer-based experimental drugs.

Orthopedic technology is the business of Ottobock SE & Co. KGaA, formerly known as Otto Bock, a German corporation with its headquarters located in Duderstadt. It is regarded as the   market leader in the prosthetics industry and a top supplier of exoskeletons, wheelchairs, and orthotics. Max Näder started his studies at Ottobock as an industrial clerk and orthopedic mechanic. He wed Marie Bock, the businesswoman's younger sister, in 1943 while on military leave. The corporation used forced laborers in World War II.

In December 2019, Ottobock will receive up to €100 million from the European Investment Bank (EIB) to aid in the development of new products by the company.